

Benjamin N Rome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/371431/publications.pdf>

Version: 2024-02-01

43
papers

1,821
citations

623734

14
h-index

289244

40
g-index

43
all docs

43
docs citations

43
times ranked

2302
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals. JAMA Internal Medicine, 2022, 182, 83. | 5.1 | 7 |
| 2 | Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling. Journal of Clinical Oncology, 2022, 40, 1102-1110. | 1.6 | 3 |
| 3 | Medicaid Spending on Drugs Marketed Without US Food and Drug Administration Approval in 2020. JAMA Internal Medicine, 2022, 182, 342. | 5.1 | 4 |
| 4 | Direct-to-Consumer Generic Drugs: A Maverick Approach or Another Exposure of Market Failures?. Annals of Internal Medicine, 2022, 175, 890-891. | 3.9 | 3 |
| 5 | State Laws and Generic Substitution in the Year After New Generic Competition. Value in Health, 2022, , . | 0.3 | 1 |
| 6 | Trends in Prescription Drug Launch Prices, 2008-2021. JAMA - Journal of the American Medical Association, 2022, 327, 2145. | 7.4 | 45 |
| 7 | Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company. Annals of Internal Medicine, 2022, 175, 1053-1055. | 3.9 | 10 |
| 8 | Federal Spending on Off-Patent Drugs That Lack Generic Competition. Journal of General Internal Medicine, 2021, 36, 821-823. | 2.6 | 4 |
| 9 | Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012â€“2018. Clinical Pharmacology and Therapeutics, 2021, 109, 367-371. | 4.7 | 26 |
| 10 | Reply to Boucher et al. Clinical Infectious Diseases, 2021, 72, e422-e423. | 5.8 | 0 |
| 11 | The Future of Drug-Pricing Transparency. New England Journal of Medicine, 2021, 384, 489-491. | 27.0 | 11 |
| 12 | Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. Milbank Quarterly, 2021, 99, 240-272. | 4.4 | 14 |
| 13 | Frequency of First Generic Drug Approvals With â€œSkinny Labelsâ€ in the United States. JAMA Internal Medicine, 2021, 181, 995-997. | 5.1 | 8 |
| 14 | Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. American Heart Journal, 2021, 233, 109-121. | 2.7 | 23 |
| 15 | Frequency Of Generic Drug Price Spikes And Impact On Medicaid Spending. Health Affairs, 2021, 40, 779-785. | 5.2 | 4 |
| 16 | Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. JAMA Network Open, 2021, 4, e218816. | 5.9 | 15 |
| 17 | Association of Californiaâ€™s Prescription Drug Coupon Ban With Generic Drug Use. JAMA - Journal of the American Medical Association, 2021, 325, 2399. | 7.4 | 2 |
| 18 | Estimating Rebates and Other Discounts Received by Medicare Part D. JAMA Health Forum, 2021, 2, e210626. | 2.2 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. <i>Value in Health</i> , 2021, 24, 804-811. | 0.3 | 8 |
| 20 | Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?. <i>JAMA Internal Medicine</i> , 2021, 181, 1034. | 5.1 | 11 |
| 21 | Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative. <i>JAMA Internal Medicine</i> , 2021, 181, 1124. | 5.1 | 4 |
| 22 | Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic. <i>Journal of General Internal Medicine</i> , 2021, 36, 3918-3921. | 2.6 | 0 |
| 23 | Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules. <i>JAMA Network Open</i> , 2021, 4, e2134463. | 5.9 | 3 |
| 24 | Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. <i>JAMA Network Open</i> , 2021, 4, e2135362. | 5.9 | 1 |
| 25 | Medicare Spending on Drugs With Accelerated Approval, 2015-2019. <i>JAMA Health Forum</i> , 2021, 2, e213937. | 2.2 | 8 |
| 26 | Raising Medicaid Rebates For Drugs With Accelerated Approval. <i>Health Affairs</i> , 2021, 40, 1935-1942. | 5.2 | 7 |
| 27 | Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1671-1675. | 5.8 | 11 |
| 28 | Effect of Shared Electronic Health Records on Duplicate Imaging after Hospital Transfer. <i>Journal of General Internal Medicine</i> , 2020, 35, 1617-1619. | 2.6 | 6 |
| 29 | US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate. <i>JAMA Internal Medicine</i> , 2020, 180, 1165. | 5.1 | 7 |
| 30 | Drug Prices, Rebates, and Discounts. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 399. | 7.4 | 4 |
| 31 | Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary. <i>JAMA Internal Medicine</i> , 2020, 180, 597. | 5.1 | 10 |
| 32 | Drug Evaluation during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 382, 2282-2284. | 27.0 | 133 |
| 33 | Sex-Based Role Misidentification and Burnout of Resident Physicians. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, . | 4.2 | 7 |
| 34 | Use of "Doctor" Badges for Physician Role Identification During Clinical Training. <i>JAMA Internal Medicine</i> , 2019, 179, 1582. | 5.1 | 16 |
| 35 | Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers. <i>Health Affairs</i> , 2017, 36, 362-370. | 5.2 | 7 |
| 36 | FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 385. | 7.4 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology. <i>Current Cardiology Reports</i> , 2014, 16, 489. | 2.9 | 26 |
| 38 | A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Arthroplasty Patients. <i>Journal of Arthroplasty</i> , 2014, 29, 1378-1382.e1. | 3.1 | 25 |
| 39 | Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis. <i>New England Journal of Medicine</i> , 2013, 368, 1675-1684. | 27.0 | 515 |
| 40 | Lifetime Risk and Age at Diagnosis of Symptomatic Knee Osteoarthritis in the US. <i>Arthritis Care and Research</i> , 2013, 65, 703-711. | 3.4 | 304 |
| 41 | Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty. <i>PLoS ONE</i> , 2013, 8, e62709. | 2.5 | 28 |
| 42 | The Dramatic Increase in Total Knee Replacement Utilization Rates in the United States Cannot Be Fully Explained by Growth in Population Size and the Obesity Epidemic. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, 201-207. | 3.0 | 409 |
| 43 | Medical Device Innovation "Is Better" Good Enough?. <i>New England Journal of Medicine</i> , 2011, 365, 1464-1466. | 27.0 | 15 |